Kaplan N M
University of Texas, Southwestern Medical Center, Dallas, USA.
J Hum Hypertens. 2000 Apr;14 Suppl 1:S87-90. doi: 10.1038/sj.jhh.1000992.
In the past few years, angiotensin II-receptor blockers have become available and are being heavily marketed and increasingly used. In various ways they differ from angiotensin-converting enzyme inhibitors (ACEIs). Until outcome data are available, they should continue to be used primarily in patients who should receive an ACEI but cannot tolerate the drug because of cough.
在过去几年中,血管紧张素II受体阻滞剂已上市,并正在大力推广且使用越来越广泛。它们在多种方面与血管紧张素转换酶抑制剂(ACEI)不同。在有结果数据可用之前,它们应继续主要用于那些因咳嗽而不能耐受ACEI但又应接受ACEI治疗的患者。